Vir Biotechnology, Inc.
Clinical trials sponsored by Vir Biotechnology, Inc., explained in plain language.
-
New shot at silencing hepatitis b virus
Disease control OngoingThis study is testing combinations of three investigational drugs (VIR-2218, VIR-3434, and/or PEG-IFNα) in people with chronic hepatitis B infection. The main goals are to see if these treatments are safe and if they can help the body clear the hepatitis B virus or significantly …
Phase: PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Apr 02, 2026 05:41 UTC
-
New drug combo targets Hard-to-Treat hepatitis d
Disease control OngoingThis study is testing two experimental drugs, VIR-2218 and VIR-3434, in people with chronic hepatitis D virus infection. The goal is to see if these drugs can safely reduce the amount of virus in the blood and improve liver health. About 95 participants will receive different com…
Phase: PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug combo challenges standard treatment for hepatitis d
Disease control OngoingThis study is testing whether a new two-drug combination (Tobevibart+Elebsiran) works better than the current standard treatment (bulevirtide) for people with chronic hepatitis D virus (HDV) infection. About 100 adults with stable liver disease will receive either the new combina…
Phase: PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New drug duo aims to knock out hepatitis d virus
Disease control OngoingThis Phase 3 trial is testing whether a combination of two drugs, tobevibart and elebsiran, can effectively treat chronic hepatitis D infection. It will compare people who receive the treatment right away to those whose treatment is delayed. The main goal is to see if the treatme…
Phase: PHASE3 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC